Foxo

FOXO Technologies is a publicly traded healthcare services and technology company executing a distinctive hybrid strategy. Its core mission is to build healthier communities by synergistically operating three divisions: an epigenetic diagnostics platform, rural hospitals, and mental/behavioral health facilities. Key achievements include a 2024 restructuring that regained SEC compliance and corrected a significant equity deficiency, followed by strategic acquisitions like Vector Biosource in 2025 to bolster its biospecimen supply chain. The strategy leverages clinical operations to generate data for refining its AI-powered epigenetic tests, while deploying those tools to improve outcomes in its own service networks.

AI and machine learning platform analyzing epigenetic markers (e.g., DNA methylation) from biological samples to assess biological aging, disease risk, and other health states.

Faces competition in two distinct arenas: against well-funded pure-play epigenetic and AI diagnostic companies, and against regional operators in rural and behavioral healthcare. Differentiation hinges on proving its synergistic model creates superior value.